ExThera Medical Taps Current Board Member and Top Finance Executive to Take the Helm
November 29, 2023

Erin Borger Named CEO at ExThera Medical

MARTINEZ, Calif. – ExThera Medical Corporation is pleased to announce Erin Borger has assumed the role of CEO of ExThera. Erin has been in finance for the last 20 years at both UBS and Morgan Stanley and brings with him a wealth of knowledge in the healthcare space. Robert Ward, Chairman, President, and Founder will continue in those roles while focusing on Research, Product Development/IP and Manufacturing Scale Up.

Erin most recently held the role of Managing Director and Director of Strategic Growth at UBS Financial Services Inc. Most notably he held the title of Market Head for Northern California where he oversaw 17 locations, and hundreds of employees. While at UBS he received the three most prestigious awards a manager could achieve including Branch Manager of the Year, Market Head of the Year, and in 2022 the Ed Connolly Award, the highest and most coveted award a field leader can earn at UBS. He also served as Executive Sponsor for the Young Professionals Network and was a Global Volunteer Award winner.

“I am honored to have the once in a lifetime opportunity to lead ExThera’s mission to save lives and I have an obligation to myself, my family, and the world to make sure ExThera succeeds.  Having reviewed companies all over the planet, ExThera has the opportunity to change the way we think about infectious disease and oncology. Our forward-looking vision for ExThera is clear, that we accelerate the availability of our life-saving technologies to the world through building a team, global commercialization, clinical trials and partnering with government entities,” said Erin Borger, CEO at ExThera.

Erin has been recognized for stabilizing and growing businesses while attracting top talent. Erin recruited Financial Advisors from Morgan Stanley, Bank of America/ML, J.P. Morgan, Wells Fargo, Janney Montgomery, First Republic, RW Baird, RBC, and elsewhere. 

“We are excited to have Erin build out the team. His ability to seek out and recruit top professionals will take ExThera to the next level, focusing on advancing ExThera technologies, in areas of oncology, sepsis, and COVID-19, some of which received breakthrough designation.” said Robert Ward, Chairman, President, and Founder of ExThera. “After 52 years in senior positions within the MedTech field, I am happy to turn over CEO duties to Erin while continuing to apply my core strengths and interests to device and biomaterials R&D/Manufacturing.”

Erin has been involved in the healthcare space for many years. He recently sat on the Board of Directors for the stem cell company Longeveron (NASD: LGVN) and is currently a Board Member of the Sepsis Alliance, the Applebaum Foundation, and ExThera Medical. Previously, Erin served as a Board Member of the National Parkinson’s Foundation, Easter Seals South Florida, F.I.N. Sea Foundation, Queen for a Day, and the Crockett Foundation. He also held roles on Avon Old Farm School’s National Council, Chris Evert Children’s Hospital Foundation Advisory Board, Cystic Fibrosis South Florida’s Advisory Board, Palisades Medical Center’s Foundation Board, and University of Miami – Miller School of Medicine’s Visiting Committee and Neurology Committee.


About ExThera Medical Corporation
ExThera Medical Corporation develops and commercializes extracorporeal blood filtration devices, including the Seraph® 100 MicroBind® Affinity Blood Filter for removing a broad range of pathogens from the bloodstream of patients. Seraph can be used in hospitals, clinics, on battlefields and in other austere environments to address nosocomial and community-acquired infections as well as those caused by battlefield wounds, pandemics, and biological warfare agents. ExThera Medical’s extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from sepsis, COVID-19, and many other severe bloodstream infections. With a growing body of outcome and health economic evidence from independent clinical studies, success in the DARPA Dialysis-Like Therapeutics program, and from successful clinical use in the US, the EU, and the Middle East, the company is well positioned to serve healthcare professionals and patients alike. The Seraph 100 attained CE Mark and is commercially available in the EU under a broad Indication For Use. The Seraph 100 has FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in the USA.

For more information visit the company’s website at www.extheramedical.com.

About Seraph 100 and the ONCOBind Procedure
As a patient’s blood flows through the Seraph 100 filter, it passes through a bed of small beads with receptors that mimic the receptors on human cells that pathogens target when they invade the body. Many harmful substances are quickly captured and adsorbed onto the surface of the beads and are thereby subtracted from the bloodstream. Seraph adds nothing to the bloodstream. It targets the pathogens that cause the infection, while it also binds and removes harmful substances generated by the pathogen and by the body’s response to the infection. Seraph’s proprietary adsorption media (the beads) constitute a flexible platform that uses immobilized (chemically bonded) heparin for its well-established blood compatibility and its unique ability to bind circulating tumor cells, bacteria, viruses, fungi, and important sepsis mediators reported to contribute to organ failure during sepsis.

For more news stories on the Seraph 100 and the ONCOBind Procedure, click here.

All information contained in this news release derives from plausible, reliable sources which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this news release or its contents. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. Persons who are in possession of this news release are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this news release to reflect events, trends, or circumstances after the date of this news release. Results from case studies (reviews) may not be predictive of future results.

MM0006 Rev B